Needham & Company analyst, Mike Matson, reiterated his Buy rating on shares of GenMark Diagnostics (NASDAQ: GNMK) and raised his ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE